SCILEX HOLDING COMPANY |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.8805 USD | +2.29% |
|
-1.93% | -56.84% |
| Apr. 16 | Scilex Issues Preliminary Q1 Sales Results for ZTlido | MT |
| Mar. 20 | Scilex Seeks FDA Approval to Add Dosing Guidance to Gout Treatment Drug Label | MT |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 564 | 199.6 | 106.6 | - | - |
| Enterprise Value (EV) 1 | 564 | 199.6 | 106.6 | 106.6 | 106.6 |
| P/E ratio | -23.5 x | -1.59 x | -2.05 x | -2.59 x | -4.4 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | 4.27 x | 1.29 x | 1.08 x | 0.88 x |
| EV / Revenue | - | 4.27 x | 1.29 x | 1.08 x | 0.88 x |
| EV / EBITDA | - | - | - | - | - |
| EV / FCF | - | - | -0.97 x | -1.18 x | -2.65 x |
| FCF Yield | - | - | -103% | -84.4% | -37.8% |
| Price to Book | - | - | - | - | - |
| Nbr of stocks (in thousands) | 141,349 | 97,837 | 121,121 | - | - |
| Reference price 2 | 3.990 | 2.040 | 0.8805 | 0.8805 | 0.8805 |
| Announcement Date | 3/7/23 | 3/12/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | 46.74 | 82.92 | 98.75 | 121.3 |
| EBITDA | - | - | - | - | - |
| EBIT 1 | - | -105.4 | -71.24 | -77.01 | -53 |
| Operating Margin | - | -225.55% | -85.92% | -77.99% | -43.69% |
| Earnings before Tax (EBT) 1 | - | -114.3 | -71.24 | -68.46 | -53 |
| Net income 1 | -23.36 | -114.3 | -71.24 | -68.46 | -58.3 |
| Net margin | - | -244.59% | -85.92% | -69.33% | -48.06% |
| EPS 2 | -0.1700 | -1.280 | -0.4300 | -0.3400 | -0.2000 |
| Free Cash Flow 1 | - | - | -109.7 | -90 | -40.3 |
| FCF margin | - | - | -132.3% | -91.14% | -33.22% |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 3/7/23 | 3/12/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 10.12 | 13.46 | 21 | 21.9 | 22.2 | 23.1 | 28.5 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | - | -38.8 | -18.34 | -31.18 | -28.85 | -26.94 | -26.49 | - |
| Operating Margin | - | -383.56% | -136.23% | -148.46% | -131.75% | -121.36% | -114.66% | - |
| Earnings before Tax (EBT) 1 | - | -35.53 | -21.39 | -31.83 | -29.1 | -26.57 | -25.55 | - |
| Net income 1 | -26.65 | -35.53 | -21.39 | -31.83 | -29.1 | -26.57 | -25.55 | - |
| Net margin | - | -351.18% | -158.87% | -151.56% | -132.87% | -119.67% | -110.61% | - |
| EPS 2 | -0.1900 | -0.6300 | -0.2500 | -0.1000 | -0.1100 | -0.1200 | -0.1000 | -0.1000 |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 8/11/23 | 11/14/23 | 3/12/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - |
| Net Cash position | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | - | -110 | -90 | -40.3 |
| ROE (net income / shareholders' equity) | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - |
| Capex | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - |
| Announcement Date | 3/7/23 | 3/12/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.8805
USD
Average target price
6.833
USD
Spread / Average Target
+676.07%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -56.84% | 107M | |
| +5.31% | 70.44B | |
| +10.97% | 8.94B | |
| -16.83% | 4.75B | |
| +43.48% | 4.5B | |
| +3.20% | 3.85B | |
| +18.82% | 2.38B | |
| -21.36% | 2.34B | |
| -29.67% | 2.2B | |
| +8.38% | 1.96B |
- Stock Market
- Equities
- SCLX Stock
- Financials Scilex Holding Company
